Zymeworks completes Theravance Biopharma buyout, adds new assets and revenue streams
Zymeworks has wrapped up its takeover of Theravance Biopharma, adding new drugs and royalties to its portfolio and pushing for steadier revenue.
Mergers & Acquisitions 1 article
Mergers & Acquisitions covers biotechnology transactions in which companies or substantial business assets change ownership through acquisition or merger. Pipeline fit, platform value, deal structure, premiums, regulatory review and post-deal integration are assessed against the scientific rationale for consolidation. Licensing belongs elsewhere because it grants rights without necessarily transferring corporate ownership; here the defining question is what is being acquired and why the buyer values it.